Bioxcel Therapeutics | Sustainability Performance
A clinical-stage biopharmaceutical entity focused on leveraging artificial intelligence to identify and develop new treatments in neuroscience and immuno-oncology. Its approach involves repurposing existing compounds and accelerating drug discovery using computational platforms.
2017
United States
11 - 50 employees
Biotechnology
$500K - 1M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#11382
Overall#2558
in United States#224
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$2.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
1.5K%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-634.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 41.9%
0.0
▼ 29.4%
0.6
2031Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
58%
Independent Directors
7 out of 12 incl. management
Overall score
22
Environment
9
Social
29
Governance
27
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
